Endothelin-mediated remodeling in aortas of diabetic rats

Diabetes/Metabolism Research and Reviews

Volumn 21, Issue 4, 2005, Pages 367-375

  Fukuda, Gen ^a   Khan, Zia A ^a   Barbin, Yousef P ^a   Farhangkhoee, Hana ^a   Tilton, Ronald G ^b   Chakrabarti, Subrata ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Endothelins; Extracellular matrix; Macroangiopathy; Oncofetal fibronectin; SMemb

Indexed keywords

ANGIOTENSINOGEN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; FIBRONECTIN; MESSENGER RNA; MYOSIN HEAVY CHAIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCLEROPROTEIN; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERY MEDIA; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC VARIABILITY; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES; THICKNESS; UPREGULATION;

ANIMALS; AORTA; DIABETES MELLITUS, EXPERIMENTAL; DNA PRIMERS; ENDOTHELIN-1; ENDOTHELINS; FIBRONECTINS; ISOXAZOLES; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SULFONAMIDES; TUNICA INTIMA; TUNICA MEDIA;

EID: 21744437756     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.527     Document Type: Article

References (51)

1. Gray RP, Yudkin JS Cardiovascular disease in diabetes mellitus. In Textbook of Diabetes (2nd edn), Pickup JC, Williams G (eds). Oxford: Blackwell Science, 1997;57.1-57.22.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-444.
3. Neubauer B, Christensen NJ, Christensen T, Gundersen HJ, Jorgensen J. Diabetic macroangiopathy. Medial calcifications, narrowing, rugosities, stiffness, norepinephrine depletion and reduced blood flow capacity in the leg arteries. Acta Med Scand Suppl 1984; 687: 37-45.
4. Chen S, Mukherjee S, Chakraborty C, Chakrabarti S. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-κB and AP-1. Am J Physiol Cell Physiol 2003; 284: 263-272.
5. Chen S, Evans T, Deng D, Cukiernik M, Chakrabarti S. Hyperhexosemia induced functional and structural changes in the kidneys: role of endothelins. Nephron 2002; 90: 86-94.
6. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 2000; 32: 1621-1629.
7. Deng D, Evans T, Mukherjee K, Downey D, Chakrabarti S. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 1999; 42: 1228-1234.
8. Evans T, Deng DX, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 2000; 49: 662-666.
9. Roy S, Cagliero E, Lorenzi M. Fibronectin overexpression in retinal microvessels of patients with diabetes. Invest Ophthalmol Vis Sci 1996; 37: 258-266.
10. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995; 44: 895-899.
11. Yamada KM. Cell surface interactions with extracellular materials. Annu Rev Biochem 1983; 52: 761-799.
12. Kornblihtt AR, Umezawa K, Vibe-Pedersen K, Baralle FE. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBO J 1985; 4: 1755-1759.
13. Border WA, Noble N. Transforming growth factor-beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
14. Fornoni A, Striker LJ, Zheng F, Striker GE. Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes 2002; 51: 499-505.
15. Fakhouri F, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C. Angiotensin II activates collagen type I gene in the renal cortex and aorta of transgenic mice through interaction with endothelin and TGF-β. J Am Soc Nephrol 2001; 12: 2701-2710.
16. Rumble JR, Gilbert RE, Cox A, Wu L, Cooper ME. Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy. J Hypertens 1998; 16: 1603-1609.
17. Van Vliet A, Baelde HJ, Vleming LJ, de Heer E, Bruijn JA. Distribution of fibronectin isoforms in human renal disease. J Pathol 2001; 193: 256-262.
18. Colombi M, Barlati S, Kornblihtt A, Baralle FE, Vaheri A. A family of fibronectin mRNAs in human normal and transformed cells. Biochim Biophys Acta 1986; 868: 207-214.
19. Nickeleit V, Kaufman AH, Zagachin L, Dutt JE, Foster CS, Colvin RB. Healing corneas express embryonic fibronectin isoforms in the epithelium, subepithelial stroma, and endothelium. Am J Pathol 1996; 149: 549-558.
20. Castellani P, Dorcaratto A, Pau A, et al. The angiogenesis marker ED-B+ fibronectin isoform in intracranial meningiomas. Acta Neurochir (Wien) 2000; 142: 277-282.
21. Khan ZA, Cukiernik M, Gonder J, Chakrabarti S. Oncofetal fibronectin in diabetic retinopathy. Invest Ophthalmol Vis Sci 2004; 45: 287-295.
22. Kuro-o M, Nagai R, Nakahara K, et al. cDNA cloning of a myosin heavy chain isoform in embryonic smooth muscle and its expression during vascular development and in arteriosclerosis. J Biol Chem 1991; 266: 3768-3773.
23. Mise N, Kimura K, Kurabayashi M, et al. Angiotensin II enhances glomerular expression of a nonmuscle myosin heavy chain, SMemb, with extracellular matrix accumulation. Nephron 2002; 90: 477-483.
24. Aikawa M, Sivam PN, Kuro-o M, et al. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res 1993; 73: 1000-1012.
25. Makino H, Kashihara N, Sugiyama H, et al. Phenotypic modulation of the mesangium reflected by contractile proteins in diabetes. Diabetes 1996; 45: 488-495.
26. A receptor antagonist. Pulm Pharmacol Ther 2000; 13: 87-97.
27. A selective endothelin antagonist. J Med Chem 2001; 44: 1211-1216.
28. Hileeto D, Cukiernik M, Mukherjee S, et al. Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium. Diabetes Metab Res Rev 2002; 18: 386-394.
29. Jensen EB, Gundersen HJ, Osterby R. Determination of membrane thickness distribution from orthogonal intercepts. J Microsc 1979; 115: 19-33.
30. Chen S, Khan ZA, Cukiernik M, Chakrabarti S. Differential activation of NF-κB and AP-1 in mediating endothelin-dependent increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab 2003; 284: E1089-E1097.
31. Vasir B, Reitz P, Xu G, Sharma A, Bonner-Weir S, Weir GC. Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-α, TGF-β, bFGF and Vimentin) in cultured and transplanted rat islets. Diabetologia 2000; 43: 763-772.
32. Kofron M, Demel T, Xanthos J, et al. Mesoderm induction in Xenopus is a zygotic event regulated by maternal VegT via TGFbeta growth factors. Development 1999; 126: 5759-5770.
33. Suzuki J, Isobe M, Aikawa M, et al. Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allografts. A study in rat and monkey models. Circulation 1996; 94: 1118-1124.
34. Inui T, James AF, Fujitani Y, et al. ETA and ETB receptors on single smooth muscle cells cooperate in mediating guinea pig tracheal contraction. Am J Physiol 1994; 266: L113-L124.
35. Jandeleit-Dahm K, Hannan KM, Farrelly CA, et al. Diabetes-induced vascular hypertrophy is accompanied by activation of Na(+)-H(+) exchange and prevented by Na(+)-H(+) exchange inhibition. Circ Res 2002; 87: 1133-1140.
36. Alessandri G, Chirivi RG, Castellani P, Nicole G, Giavazzi R, Zardi L. Isolation and characterization of human tumor-derived capillary endothelial cells: role of oncofetal fibronectin. Lab Invest 1998; 78: 127-128.
37. Hashimoto-Uoshima M, Yan YZ, Schneider G, Aukhil I. The alternatively spliced domains EIIIB and EIIIA of human fibronectin affect cell adhesion and spreading. J Cell Sci 1997; 110: 2271-2280.
38. Takeda Y, Miyamori I, Yoneda T, Takeda R. Production of endothelin-1 from the mesenteric arteries of streptozotocin-induced diabetic rats. Life Sci 1991; 8: 2553-2556.
39. Chakrabarti S, Khan ZA, Cukiernik M, Fukuda G, Chen S, Mukherjee S. Alteration of endothelins: a common pathogenetic mechanism in chronic diabetic complications. Int J Exp Diabetes Res 2002; 3: 217-231.
40. A-receptor antagonist. Circulation 1997; 96: 1593-1597.
41. Weigert C, Brodbeck K, Klopfer K, Häring HU, Schleicher ED. Angiotensin II induces human TGF-β1 promoter activation: similarity to hyperglycaemia. Diabetologia 2002; 45: 890-898.
42. Rabelink TJ, Bakris GL. The renin-angiotensin system in diabetic nephropathy: the endothelial connection. Miner Electrolyte Metab 1998; 24: 381-388.
43. Cooper ME, Rumble J, Komers R, Du HC, Jandeleit K, Chou ST. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. Diabetes 1994; 43: 1221-1228.
44. Cao Z, Hulthen UL, Allen TJ, Cooper ME. Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action. J Hypertens 1998; 16: 793-799.
45. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-461.
46. Benigni A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44: 440-444.
47. Ferrer P, Valentine M, Jenkins-West T, et al. Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries. J Cardiovasc Pharmacol 1995; 26: 908-915.
48. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
49. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384: 353-355.
50. Depre C, Young ME, Ying J, et al. Streptozotocin-induced changes in cardiac gene expression in the absence of severe contractile dysfunction. J Mol Cell Cardiol 2000; 32: 985-996.
51. Mori S, Takemoto M, Yokote K, Asaumi S, Saito Y. Hyperglycemia-induced alteration of vascular smooth muscle phenotype. J Diabetes Complications 2002; 16: 65-68.